Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „DLBCL“
Suchtreffer
Begriffe & Kennungen
Columvi · 4.8 · 15 Adverse reactions occurring in relapsed or refractory DLBCL patients treated with Columvi in combination wi
Eintrag öffnenColumvi · 4.8 · 17 Table 7. Adverse reactions reported in patients with relapsed or refractory DLBCL treated with Columvi in c
Eintrag öffnenColumvi · 4.8 · Adverse reactions occurring in relapsed or refractory DLBCL patients treated with Columvi monotherapy (n=145)
Eintrag öffnenColumvi · 4.8 · Table 6. Adverse reactions reported in patients with relapsed or refractory DLBCL treated with Columvi monothe
Eintrag öffnenItuxredi · 4.8 · Experience from paediatric DLBCL/BL/BAL/BLL
Eintrag öffnenKymriah · 4.8 · 16 T-cell immunogenicity responses were not observed in paediatric and young adult B-cell ALL, adult r/r DLBCL
Eintrag öffnenKymriah · 4.8 · All adult DLBCL patients had Grade 3 and 4 cytopenias at some time after Kymriah infusion. Grade 3 and 4 cytop
Eintrag öffnenKymriah · 4.8 · Cytokine release syndrome was graded per Penn criteria in the paediatric and young adult B-cell ALL and DLBCL
Eintrag öffnenKymriah · 4.8 · DLBCL The adverse reactions described in this section were characterised in 115 patients infused with Kymriah
Eintrag öffnenKymriah · 4.8 · In DLBCL patients severe infections (Grade 3 and higher), which can be life-threatening or fatal, occurred in
Eintrag öffnenKymriah · 4.8 · In the ongoing clinical study in DLBCL (N=115), cytokine release syndrome was reported in 57% of patients (23%
Eintrag öffnenKymriah · 4.8 · Safety assessment was based on a total of 424 patients (with paediatric and young adult B-cell ALL, DLBCL and
Eintrag öffnenMabThera · 4.8 · 20 Experience from paediatric DLBCL/BL/BAL/BLL
Eintrag öffnenMinjuvi · 4.8 · Summary of the safety profile Patients with relapsed or refractory DLBCL The safety of tafasitamab in patients
Eintrag öffnenMinjuvi · 4.8 · Table 2: Adverse reactions in patients with relapsed or refractory DLBCL who received tafasitamab in combinati
Eintrag öffnenPolivy · 4.8 · 12 a ADR associated with fatal outcome b ADRs observed in relapsed or refractory DLBCL only. c ADRs observed i
Eintrag öffnenPolivy · 4.8 · In previously treated DLBCL patients treated with Polivy plus BR: The most frequently reported (≥ 30%) ADRs
Eintrag öffnenPolivy · 4.8 · In previously untreated DLBCL patients treated with Polivy plus R-CHP: The most frequently-reported (≥ 30%)
Eintrag öffnenRiximyo · 4.8 · Experience from paediatric DLBCL/BL/BAL/BLL
Eintrag öffnenYescarta · 4.8 · DLBCL and HGBL that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunot
Eintrag öffnen